Hanmi Pharm's new complex drug of dyslipidemia, Rosuzet, was launched in Mexico, which is considered the largest pharmaceutical market in Latin America.
Hanmi Pharmaceutical announced on March 4 that it has released Rosuzet's Mexican product name "NAXZALLA" in three doses (10/5mg, 10/10mg, and 10/20mg) through its partner, MSD.
Hanmi Pharm had originally signed an export contract with MSD of the U.S. to 23 global countries, but the contract was changed when MSD recently established a new corporation in charge of specific specialist drug businesses such as the cardiovascular field.
In July last year, MSD obtained a marketing license for "NAXZALLA" from the Mexican Medical Authority (COFEPRIS).
The Mexican drug market is worth 15 trillion won annually, the second-largest market after Brazil in Latin America, and is growing by more than 10% every year.
In particular, the Mexican national obesity rate took second place in the world after the United States, and the relevant medicines market is rapidly growing.
In addition to exporting countries signed with MSD, Hanmi Pharm is continuing its efforts to launch Rosuzet locally in many countries, including Argentina and those in Asia, and Africa.
Woo Jong-soo, CEO of Hanmi Pharm, said, "Rosuzet is a complex new drug developed by a Korean pharmaceutical company that has topped the list of prescription sales in Korea."
